STING1 and neoplasm: Figure 2 illustrates the relationship between cGAS-STING agonists and antitumor immunity. Ongoing preclinical and clinical studies have demonstrated that various therapeutic modalities can synergize with cGAS-STING agonists to remodel the tumor immune microenvironment and enhance antitumor effects (47).